Have scientists discovered a cure for Alzheimer's?

Scientists were amazed when a 20-year-old hay fever drug was found to be highly effective in treating dementia. Jeremy Laurance reports on a startling discovery

A hundred years after Alzheimer's disease was discovered, a cure for the degenerative condition that strips sufferers of their memory and personality remains a dream. The main advances have been in drugs to control symptoms such as agitation and restlessness. Restoring memory and cognitive ability has proved much harder.

That is why the publication last week of research showing that an old Russian drug once prescribed for hay fever may be the most effective treatment yet for the devastating condition has captured the attention of scientists and patients' groups.

A single 20mg pill of the drug, called Dimebon, taken three times a day, appears to be twice as effective in improving cognitive performance and preventing deterioration in memory as existing drugs.

The discovery was greeted by charities as perhaps the most exciting development in treatment of the disease. Existing drugs – cholinesterase inhibitors such as Aricept – have limited effects and were introduced over a decade ago.

According to the American researchers who led the trial, Dimebon is the furthest advanced of 65 agents being investigated for Alzheimer's, and holds the most promise.

However, British experts cautioned that the results were from a single trial of the drug, which is not licensed for Alzheimer's, and said further studies were necessary. A second international trial of the drug, which started last month in the USA, Europe and South America, is due to be completed by the end of the year.

Dimebon was used as an antihistamine in Russia 20 years ago, but it was withdrawn from the market when newer drugs superseded it. Investigations by the Russian Academy of Sciences revealed that it had a potential neuroprotective effect and it was bought by a US company, Medivation.

The company asked Professor Rachelle Doody, director of the Alzheimer's and Memory Disorders Center at the Baylor College of Medicine in Houston, to lead the randomised trial run by American and Russian scientists. It involved 183 patients with mild to moderate Alzheimer's in 11 hospitals in Russia.

Doody, who set up the Houston centre in 1987, is one of the world's leading researchers on Alzheimer's. She was the lead investigator in the trials of Aricept, the best-known existing Alzheimer's drug.

The results of the Dimebon trial she led, published last week in The Lancet, show that it improved performance on all five rating scales used to assess Alzheimer's patients, including cognitive performance, behaviour and capacity to carry out ordinary daily activities. Patients taking the drug scored better than they did at the start of the study, while those taking placebo got worse over the initial six-month period of the trial.

In a smaller group of patients who continued with the drug for a further six months, an even greater gap of 6.9 points on the cognitive performance test opened up between those on the drug and those on placebo. This compares with a 2.5- to three-point gain in trials of existing drugs.

Doody said: "I was surprised that all five of the outcome measures were positive and that the benefit [against placebo] widened over time. You don't see that with the other drugs... But this wasn't a comparison study – you can't say that makes Dimebon better than the other drugs."

She added: "I am very happy with the results. They show a clear signal and I am hopeful that the new international study which started last month will replicate them. US regulators have indicated that the trials are potentially acceptable as evidence for approval [for a licence]. There are a couple of dozen agents I am working on, and 65 that I follow, and the good news is that this is the furthest along in Alzheimer's research."

Clive Ballard of the Alzheimer's Society said the findings were "encouraging" and the discovery of a new application for an old drug was "potentially exciting". But it was a single trial of a small size and the results needed confirming, he said.

Caution was also expressed by Professors Alastair Burns of the University of Manchester and Robin Jacoby of the University of Oxford, who wrote in a commentary in The Lancet: "Addition of treatment options is good news for patients and clinicians – it promotes choice and offers the possibility of bespoke treatment packages which maximise the chances of response. [The] trial shows that Dimebon is better than placebo which is no mean feat considering the positive placebo responses in dementia."

But Jacoby said that he retained a "healthy scepticism" about the findings. "They need to be replicated before I will start prescribing it," he said.

If the results are replicated, it will be a boost for a new approach to drug research – taking old drugs and investigating their potential in other areas of medicine. Old drugs can go rapidly into clinical trials for new conditions because they are known to be safe. This speeds up development and cuts the cost.

A cure for Alzheimer's is not imminent, but it's good news that an old drug may be an effective treatment. Everything hangs on the second Dimebon trial now under way.

Alzheimer's: the facts

About 400,000 people suffer from Alzheimer's in the UK and 25 million worldwide.

It is the commonest form of dementia, costing £17bn in the UK for care and treatment.

The condition is caused by the accumulation of protein deposits in the brain, producing the dementia symptoms.

There are three drugs that claim to halt the progress of the disease (but not to reverse it) – Aricept, Reminyl and Exelon.

In 2006, the NHS's use of these drugs was restricted to the moderate stage of the disease by the National Institute for Clinical Excellence because of their limited effect.

There are currently no drugs available on the NHS for the tens of thousands of patients in the UK with mild Alzheimer's.

Life and Style
A monstrous idea? Body transplants might no longer be science fiction
Science An Italian neurosurgeon believes so - and it's not quite as implausible as it sounds, says Steve Connor
Sport
Demba Ba (right) celebrates after Besiktas win on penalties
footballThere was no happy return to the Ataturk Stadium, where the Reds famously won Champions League
Arts and Entertainment
Natural beauty: Aidan Turner stars in the new series of Poldark
arts + ents
News
Mia Freedman, editorial director of the Mamamia website, reads out a tweet she was sent.
arts + ents
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
News
people
Arts and Entertainment
The write stuff: masters of story-telling James Joyce, left, and Thomas Hardy
arts + ents...begging to differ, John Walsh can't even begin to number the ways
Sport
Jose Mourinho on Sky Sports
footballEXCLUSIVE COLUMN Paul Scholes: It was not a leg-breaking tackle, as the Chelsea manager had claimed
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Bookkeeper

    £23000 - £26000 per annum: Recruitment Genius: This small, friendly, proactive...

    Recruitment Genius: Photographic Event Crew

    £14500 - £22800 per annum: Recruitment Genius: This is a fantastic opportunity...

    Recruitment Genius: Software Developers - .NET / ASP.NET / WebAPI / JavaScript

    Negotiable: Recruitment Genius: A Software Developer is required to join a lea...

    Austen Lloyd: Corporate Tax Solicitor - City

    Excellent Salary: Austen Lloyd: A first rate opportunity to join a top ranking...

    Day In a Page

    HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

    Scientists hail daily pill that protects against HIV infection

    Breakthrough in battle against global scourge – but will the NHS pay for it?
    How we must adjust our lifestyles to nature: Welcome to the 'Anthropocene', the human epoch

    Time to play God

    Welcome to the 'Anthropocene', the human epoch where we may need to redefine nature itself
    MacGyver returns, but with a difference: Handyman hero of classic 1980s TV series to be recast as a woman

    MacGyver returns, but with a difference

    Handyman hero of classic 1980s TV series to be recast as a woman
    Tunnel renaissance: Why cities are hiding roads down in the ground

    Tunnel renaissance

    Why cities are hiding roads underground
    'Backstreet Boys - Show 'Em What You're Made Of': An affectionate look at five middle-aged men

    Boys to men

    The Backstreet Boys might be middle-aged, married and have dodgy knees, but a heartfelt documentary reveals they’re not going gently into pop’s good night
    Crufts 2015: Should foreign dogs be allowed to compete?

    Crufts 2015

    Should foreign dogs be allowed to compete?
    10 best projectors

    How to make your home cinema more cinematic: 10 best projectors

    Want to recreate the big-screen experience in your sitting room? IndyBest sizes up gadgets to form your film-watching
    Manchester City 1 Barcelona 2 player ratings: Luis Suarez? Lionel Messi? Joe Hart? Who was the star man?

    Manchester City vs Barcelona player ratings

    Luis Suarez? Lionel Messi? Joe Hart? Who was the star man at the Etihad?
    Arsenal vs Monaco: Monaco - the making of Gunners' manager Arsene Wenger

    Monaco: the making of Wenger

    Jack Pitt-Brooke speaks to former players and learns the Frenchman’s man-management has always been one of his best skills
    Cricket World Cup 2015: Chris Gayle - the West Indies' enigma lives up to his reputation

    Chris Gayle: The West Indies' enigma

    Some said the game's eternal rebel was washed up. As ever, he proved he writes the scripts by producing a blistering World Cup innings
    In Ukraine a dark world of hybrid warfare and murky loyalties prevails

    In Ukraine a dark world of hybrid warfare

    This war in the shadows has been going on since the fall of Mr Yanukovych
    'Birdman' and 'Bullets Over Broadway': Homage or plagiarism?

    Homage or plagiarism?

    'Birdman' shares much DNA with Woody Allen's 'Bullets Over Broadway'
    Broadchurch ends as damp squib not even David Tennant can revive

    A damp squib not even David Tennant can revive

    Broadchurch, Series 2 finale, review
    A Koi carp breeding pond, wall-mounted iPads and a bathroom with a 'wellness' shower: inside the mansion of Germany's 'Bishop of Bling'

    Inside the mansion of Germany's 'Bishop of Bling'

    A Koi carp breeding pond, wall-mounted iPads and a bathroom with a 'wellness' shower